MEDIA ALERT: Mirapath to Host the Engineering Lab Symposium

CUPERTINO, Calif.--(BUSINESS WIRE)-- Mirapath, Inc., a trusted provider of data center and engineering lab infrastructure, today announced that it will host the Engineering Lab Symposium on Tuesday, November 8, in Santa Clara, California.

The Engineering Lab Symposium is an annual event exclusively focused on engineering lab challenges, trends, and best practices. This year’s featured speaker is Dan Lunderville, Manager of Global Customer Labs at Palo Alto Networks. Mr. Lunderville will share his global lab automation journey including different automation levels, building an automation team, and capturing ROI. APC by Schneider Electric, Emerson, Lantronix, Netscout, Panduit, Raritan, and Spirent are sponsoring the event.

What: Engineering Lab Symposium

Who: Dan Lunderville, Manager of Global Customer Labs at Palo Alto Networks

When: Tuesday, November 8, 2016, 11:00 AM – 2:30 PM

Where: Hyatt Regency - 5101 Great America Parkway, Santa Clara, CA 95054

RSVP: [email protected]Complimentary passes are available to members of the media.

For more information, visit www.engineeringlabsymposium.com.

About Mirapath:

Mirapath is a fast growing data center and engineering lab infrastructure provider. Trusted by Fortune 500 and Silicon Valley 150 companies, Mirapath provides the framework for tailored, scalable, and high-performing data centers and engineering labs. Mirapath designs, deploys, and manages infrastructure for high-growth and enterprise organizations including Palo Alto Networks, Pandora, VMware, Cisco, HP, Pure Storage, Tesla, and Google. Learn more at www.mirapath.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161107005256/en/

Mirapath, Inc.
Normina Leonardo, 408-207-1765
Director of Marketing
[email protected]

Source: Mirapath, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
• Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
• Akkodis and Hamburg Public Transport Association Showcase hvv mia at InnoTrans 2026, Demonstrating the Future of AI-Powered Mobility